The pharmaceutical industry is famous for its high R&D costs. But there are low-risk, capital-efficient alternatives to new drug development. Algernon Pharmaceuticals Inc. is exploring one such option: drug repurposing. Its current work includes research into microdoses of DMT as a treatment for acute stroke. Algernon CEO, Christopher J. Moreau, gives us some insight in this interview.



View full interview transcript by clicking below:

Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment